PTGS2 and neoplasm: One of the concerns of inhibiting COX-2 activity is that the consequent reduction in cytokine production may abolish the antitumor immune response necessary for long-term protection against tumor recurrence [169] and removal of residual or non-PDT damaged tumor cells in immunocompetent hosts [83, 84].